Argus Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to “Buy”

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Argus from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Benzinga reports. The firm currently has a $850.00 target price on the biopharmaceutical company’s stock. Argus’ target price indicates a potential upside of 12.10% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Leerink Partners lifted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $804.26.

Regeneron Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ REGN opened at $758.27 on Thursday. Regeneron Pharmaceuticals has a one year low of $541.00 and a one year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business’s fifty day moving average price is $785.06 and its 200-day moving average price is $720.91. The stock has a market capitalization of $78.07 billion, a PE ratio of 18.74, a P/E/G ratio of 1.47 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the firm posted $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Insider Activity

In related news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 3,946 shares of company stock worth $3,302,458. 6.97% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 109,838 shares of the biopharmaceutical company’s stock valued at $68,488,000 after acquiring an additional 686 shares during the last quarter. Andra AP fonden increased its position in shares of Regeneron Pharmaceuticals by 583.2% in the second quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock worth $18,028,000 after purchasing an additional 24,680 shares during the last quarter. State Street Corp raised its stake in Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after purchasing an additional 170,210 shares in the last quarter. Tidal Investments LLC lifted its position in Regeneron Pharmaceuticals by 10.7% during the second quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock valued at $27,371,000 after purchasing an additional 4,244 shares during the last quarter. Finally, National Pension Service grew its stake in Regeneron Pharmaceuticals by 2.2% in the 2nd quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock worth $236,830,000 after buying an additional 8,264 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Expanded Sanofi alliance provides significant financial and pipeline upside. Regeneron will receive $1 billion upfront and could earn up to $7 billion in milestone payments by adding REGN20423, a long-acting IL-13 antibody, an IL-4xIL-13 bispecific, and two additional preclinical antibodies to the collaboration. The companies will share development and commercialization costs and future profits, reducing Regeneron’s financial burden while expanding its immunology pipeline. Sanofi and Regeneron expand global alliance press release
• Positive Sentiment: Weight-loss combination data strengthen Regeneron’s metabolic-disease opportunity. An experimental Regeneron drug reduced muscle loss by 50% when combined with Novo Nordisk’s semaglutide versus semaglutide alone in an obesity study. Preserving muscle mass could help differentiate future therapies, though the asset remains investigational. Regeneron drug muscle-loss study
• Neutral Sentiment: Analyst opinions are mixed. Zacks upgraded REGN to “strong buy,” and broader sell-side coverage reflects a “moderate buy” view. However, Royal Bank of Canada reaffirmed a “sector perform” rating with a $737 price target, below the referenced share price, suggesting limited near-term valuation upside. Royal Bank of Canada Regeneron rating
• Negative Sentiment: Eylea faces increasing competitive pressure. Kodiak Sciences reported Phase 3 results indicating its eye-disease candidates delivered comparable vision outcomes to Eylea with dosing approximately every six months, versus Eylea’s more frequent regimen. If confirmed, longer-lasting alternatives could threaten Regeneron’s ophthalmology revenue and market share. Regeneron eye-disease competition analysis

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.